Sign in

SKYE on Nasdaq

Skye Bioscience, Inc.

In its 2026 annual report the company says: “Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1—a key GPCR involved in metabolic regulation.”3 It is headquartered in San Diego, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerSKYE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inNV2
  • Business address11250 El Camino Real, Suite 100, San Diego, Ca 921302
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$58.2M in 2025+777% since 2019
-$60.0M-$40.0M-$20.0M02019: -$6.6M-$6.6M20192020: -$6.3M-$6.3M2020−5%2021: -$7.8M-$7.8M2021+25%2022: -$18.3M-$18.3M2022+133%2023: -$34.7M-$34.7M2023+90%2024: -$30.2M-$30.2M2024−13%2025: -$58.2M-$58.2M2025+93%
Net income456789-$55.9M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2019: $1.1M$1.1M20192020: -$6.6M-$6.6M20202021: -$8.5M-$8.5M2021+30%2022: -$19.5M-$19.5M2022+129%2023: -$37.6M-$37.6M2023+93%2024: -$26.6M-$26.6M2024−29%2025: -$55.9M-$55.9M2025+111%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$42.4M$18.7M
General and administrative$15.8M$17.7M
Change in estimate for legal contingencies$0-$4.2M
Income from insurance recovery$0-$2.0M
Total operating expenses$58.2M$30.2M
Operating loss-$58.2M-$30.2M
Interest expense$0$749.3K
Interest income$1.9M$3.0M
Gain from asset sale-$360.8K-$1.4M
Other expense$502$2.2K
Total other (income) expense, net-$2.2M-$3.6M
Loss before income taxes-$55.9M-$26.6M
Provision for income taxes$5.4K$10.1K
Net loss-$55.9M-$26.6M
Basic (in dollars per share)-$1.41-$0.73
Diluted (in dollars per share)-$1.41-$0.73
Basic (in shares)39.7M shares36.5M shares
Diluted (in shares)39.7M shares36.5M shares

Compare Skye Bioscience, Inc. with another company

Corporate structure

Skye Bioscience, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Skye Bioscience, Inc.

  • Skye Bioscience, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Skye Bioscience, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.7M9 Dec 31, 2025$1.7M9 Dec 31, 2024+0.4%
Accumulated depreciation$773.6K9 Dec 31, 2025$233.5K9 Dec 31, 2024+231.3%
Property and equipment, net$898.9K9 Dec 31, 2025$1.4M9 Dec 31, 2024−37.3%
Operating-lease assets (leased space)$266.6K9 Dec 31, 2025$449.9K9 Dec 31, 2024−40.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.9M9 Dec 31, 2025$68.4M9 Dec 31, 2024−91.4%
Marketable securities, current$19.9M9 Dec 31, 2025$09 Dec 31, 2024

Properties, in its own words

We lease our principal executive offices and corporate offices, which are located at 11250 El Camino Real Suite 100, San Diego, CA 92130. Our lease for this facility expires on October 31, 2026. We believe that our facilities are adequate to meet our current needs, and that suitable alternative spaces will be available in the future on commercially reasonable terms, if required.

Item 2 of the 10-K filed Mar 10, 2026.3

Leadership

Who has led Skye Bioscience, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yosbani Mendez2014
  2. John B. Hollister2014
  3. Punit Dhillon2020–now

Chair

  1. Cosmas N. Lykos2014–2018

Chief financial officer

  1. Yosbani Mendez2014
  2. Elizabeth Berecz2014–2018
  3. Douglas A. Cesario2018
  4. Elena Traistaru2020
  5. Kaitlyn Melanie Arsenault2021–2026
  6. John P. Sharp2026–now

Chief operating officer

  1. Tuan Tu Diep2026–now
201520202025
Board members and other officers (22)

Former names

  • Emerald Bioscience, Inc.Mar 25, 2019 to Jan 7, 20212
  • Nemus Bioscience, Inc.Nov 3, 2014 to Mar 14, 20192
  • LOAD GUARD LOGISTICS, INC.Nov 8, 2012 to Oct 30, 20142
  • LOAD GUARD TRANSPORTATION, INC.Mar 25, 2011 to Nov 7, 20122

Timeline

  1. Sep 11, 20268-K Ended a material agreement; Executive or director change; Other events41
  2. Aug 24, 20268-K Entered a material agreement; Unregistered sale of shares42
  3. Aug 20, 20268-K Change to shareholders' rights43
  4. Aug 19, 20268-K Listing notice or transfer44
  5. Aug 14, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights45
  6. Jun 23, 20268-K Other events46
  7. May 29, 20268-K Bylaws or fiscal year changed; Shareholder vote47
  8. May 15, 20268-K Listing notice or transfer48
  9. Apr 6, 20268-K Executive or director change49
  10. Apr 3, 20268-K Executive or director change50
  11. Mar 19, 20268-K Listing notice or transfer51
  12. Mar 10, 20268-K Results of operations52
  13. Aug 11, 2020New chief executive Punit Dhillon becomes CEO12
  14. Nov 10, 2014New chief executive John B. Hollister becomes CEO14
  15. Jan 29, 2014New chief executive Yosbani Mendez becomes CEO13

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($2.56) a share, on Nov 10, 2025.53

When it reported results

  1. Mar 10, 2026Reported quarterly or annual results52
  2. Nov 10, 2025Reported quarterly or annual results54
  3. Aug 7, 2025Reported quarterly or annual results55
  4. May 8, 2025Reported quarterly or annual results56
  5. Mar 20, 2025Reported quarterly or annual results57
  6. Nov 7, 2024Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

275 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 119 insider forms, 20 large holders, 3 private raises, 57 other. The latest 20:

  1. Oct 14, 2026SCHEDULE 13G EDGAR
  2. Sep 24, 2026SCHEDULE 13D/A EDGAR
  3. Sep 24, 20264 EDGAR
  4. Sep 24, 20264 EDGAR
  5. Sep 18, 20264 EDGAR
  6. Sep 18, 20264 EDGAR
  7. Sep 11, 2026DEFA14A EDGAR
  8. Sep 11, 20268-K EDGAR
  9. Aug 24, 2026DEFA14A EDGAR
  10. Aug 24, 20268-K EDGAR
  11. Aug 20, 2026DEFA14A EDGAR
  12. Aug 20, 20268-K/A EDGAR
  13. Aug 20, 20264 EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 19, 2026DEFA14A EDGAR
  16. Aug 19, 20268-K EDGAR
  17. Aug 18, 2026SCHEDULE 13D/A EDGAR
  18. Aug 14, 2026DEFA14A EDGAR
  19. Aug 14, 202610-Q EDGAR
  20. Aug 14, 20268-K EDGAR

The 275 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

34 open-market trades by officers, directors and large owners since October 2021: 4 buys and 30 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Schwab Andrew J.DirectorSale119,379$1.61$192.2KForm 4
Sep 23, 20265AM Ventures II LP10% ownerSale119,379$1.61$192.2KForm 4
Sep 22, 2026Schwab Andrew J.DirectorSale28,700$1.65$47.4KForm 4
Sep 22, 20265AM Ventures II LP10% ownerSale28,700$1.65$47.4KForm 4
Sep 16, 2026Schwab Andrew J.DirectorSale33,892$1.91$64.7KForm 4
Sep 16, 2026PARMAR KUSH10% ownerSale33,892$1.91$64.7KForm 4
Aug 20, 2026Schwab Andrew J.DirectorSale7,700$0.32$2.5KForm 4
Aug 20, 20265AM Partners II, LLC10% ownerSale7,700$0.32$2.5KForm 4
Aug 19, 2026Schwab Andrew J.DirectorSale68,140$0.35$23.8KForm 4
Aug 19, 20265AM Partners II, LLC10% ownerSale68,140$0.35$23.8KForm 4
Aug 18, 2026Schwab Andrew J.DirectorSale300,000$0.38$114.0KForm 4
Aug 18, 20265AM Partners II, LLC10% ownerSale300,000$0.38$114.0KForm 4
Aug 22, 2025Schwab Andrew J.DirectorSale170,449$3.42$582.9KForm 4
Aug 22, 2025ROCKLAGE SCOTT M10% ownerSale170,449$3.42$582.9KForm 4
Aug 21, 2025Schwab Andrew J.DirectorSale60,956$3.57$217.6KForm 4
Aug 21, 2025ROCKLAGE SCOTT M10% ownerSale60,956$3.57$217.6KForm 4
Nov 18, 2024ARSENAULT KAITLYNChief Financial OfficerSale43,026$4.99$214.7KForm 4
Nov 18, 2024Diep Tuan TuChief Operating OfficerSale19,489$4.99$97.2KForm 4
Nov 18, 2024ARSENAULT KAITLYNChief Financial OfficerSale43,206$4.99$215.6KForm 4
Nov 18, 2024DHILLON PUNITChief Executive OfficerSale82,546$4.99$411.9KForm 4

All 34 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Punit DhillonChief Executive Officer45$610.0K$1.4M68
2025Kaitlyn ArsenaultFormer Chief Financial Officer$450.0K$888.6K68
2025Tu DiepChief Operating Officer45$440.0K$875.9K68
2024Punit DhillonChief Executive Officer45$458.3K$6.1M68
2024Kaitlyn ArsenaultFormer Chief Financial Officer$365.0K$2.3M68
2024Tu DiepChief Operating Officer45$358.3K$2.2M68

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 13, 2024Raised $40 million in a private offering of equity Form D: 13 investors so far Form D
  2. Jan 31, 2024Raised $50 million in a private offering of equity Form D: 11 investors so far Form D
  3. Aug 15, 2023Raised $62.3 million in a private offering of securities Form D: 12 investors so far Form D

SEC filer profile

How Skye Bioscience, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSkye Bioscience, Inc.1
  • CIK0001516551
  • Employer ID (EIN)45-06928823
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11250 El Camino Real, Suite 100, San Diego, CA 921301
  • Phone(858) 410-02661
  • Shares outstanding35,421,413 as of Aug 10, 202611
  • Public float$129.5M as of Jun 30, 20253
  • AuditorCBIZ CPAs P.C., Morristown, New Jersey PCAOB ID 199; it also attests to the company’s internal control over financial reporting3
  • On EDGAR sinceMar 25, 20111
  • Filings629 in all: 4 (142), 8-K (116), 424B3 (48), 10-Q (41), 3 (36), CORRESP (22), UPLOAD (20), EFFECT (18)1
    All 49 form types

    D (14), 10-K (13), SC 13D/A (13), S-1/A (11), S-1 (10), S-8 (10), SC 13G (9), DEFA14A (8), POS AM (8), SC 13G/A (8), 4/A (7), 8-K/A (6), CT ORDER (6), DEF 14A (6), SC 13D (5), 144 (4), DEF 14C (4), SCHEDULE 13D/A (4), 3/A (3), D/A (3), PRE 14A (3), PRE 14C (3), S-3 (3), 424B4 (2), ARS (2), PREM14A (2), S-1MEF (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 424B2 (1), 424B5 (1), 5 (1), 8-A12B (1), 8-A12G (1), AW (1), CERT (1), DEFM14A (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 10, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 16, 2026
    Latest 8-K (8-K) Sep 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001SKYENasdaq Global Market

From the cover page of the 10-K filed Mar 10, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Skye Bioscience, Inc. names in Item 1A of its 10-K filed Mar 10, 2026: 74 risks under these headings, as written.3

  • Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
  • We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
  • Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, and if we are unable to continue, you may lose your entire investment.
  • We are heavily dependent on the success of nimacimab, which will require significant additional efforts to develop and may prove not to be viable for commercialization.
  • We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.
  • We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
  • Our ability to raise capital may be limited by applicable laws and regulations.
  • Public opinion and scrutiny of treatments for obesity and overweight may impact public perception of us or nimacimab, or may adversely affect our ability to conduct our business and our business plans.
  • Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization
  • We may expend our limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Nonclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. The results of prior clinical studies and preclinical studies are not necessarily predictive of future results, and may not be favorable, or receive regulatory approval on a timely basis, if at all.
  • Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
The other 62 risks
  • If we experience delays or difficulties in the enrollment or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Serious adverse events or undesirable side effects or other unexpected properties of nimacimab may be identified during development or after approval that could delay, prevent or cause the withdrawal of marketing approval, limit the commercial potential, or result in significant negative consequences following marketing approval.
  • As an organization, we have never conducted later-stage clinical trials or submitted an NDA or BLA, and may be unable to do so for any of our product candidates.
  • Nimacimab is subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize nimacimab.
  • We have conducted clinical trials for our product candidates outside of the United States and we may do so for our product candidates in the future. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.
  • Preliminary, topline and interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The manufacture and maintenance of our clinical product candidate is complex and we may encounter difficulties in production and maintenance, particularly with respect to clinical material inventory, acquisition of materials, process development or scaling-up of our manufacturing capabilities.
  • Disruptions at the FDA and other government agencies caused by changes in U.S. federal government funding or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • Additional time may be required to obtain marketing authorizations for any product candidates that we develop as biologic-device combination products.
  • Risks Related to Our Reliance on Third Parties
  • We expect to continue to rely on third parties, such as CROs, to conduct some or all of our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates.
  • We rely on, and expect to continue relying on, third party contract manufacturing organizations to manufacture and supply nimacimab for us. This reliance on third parties increases the risk that we will not have sufficient quantities of nimacimab or such quantities at an acceptable cost, which could delay or impair our development efforts.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • If we fail to enter and maintain successful collaborative arrangements or strategic alliances for our product candidates, we may have to reduce or delay our product candidate development or increase our expenditures.
  • Risks Related to Commercialization
  • Even if we receive marketing approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.
  • Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
  • Even if nimacimab or our future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.
  • The successful commercialization of nimacimab, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.
  • If the market opportunities for any of our product candidates are smaller than we estimate, even assuming approval of a product candidate, our future revenue may be adversely affected, and our business may suffer.
  • We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
  • Our future growth may depend, in part, on our ability to commercialize products in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
  • Risks Related to Our Business Operations and Industry
  • Our ability to become profitable and continue as a going concern will be dependent on our ability to attract, employ and retain highly qualified personnel.
  • We may encounter difficulties in managing our growth and expanding our operations successfully.
  • We are subject to various foreign, federal and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.
  • Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could have a material adverse effect on our business, financial condition or results of operations.
  • Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our nimacimab development program, which could materially affect our results.
  • Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.
  • If product liability or state consumer protection act lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.
  • We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.
  • Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • We are currently subject to lawsuits, and in the future may be subject to additional lawsuits, that could divert its resources and result in the payment of significant damages and other remedies.
  • The increasing use of social media and artificial intelligence-based platforms presents new risks and challenges.
  • Risks Related to Our Intellectual Property
  • Our success depends on our ability to protect our intellectual property and our proprietary technologies, and if we are unable to protect our intellectual property and technologies, our business will suffer.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be material and adversely affected.
  • We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
  • Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
  • Changes in U.S. patent law, or laws in other countries or jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we do not obtain patent term extension for our product candidates, our business may be materially harmed.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
  • Risks Related to Our Common Stock
  • The trading price of our common stock has been volatile with substantial price fluctuations on heavy volume, which could result in substantial losses for purchasers of our common stock and existing stockholders.
  • Our failure to meet the continued listing requirements of the Nasdaq, including the minimum closing bid price requirement, could result in a delisting of our common stock.
  • We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.
  • Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.
  • The consent rights of our January PIPE Investors pursuant to the January 2024 PIPE SPA may adversely affect our ability to pursue certain strategic transactions.
  • We issued pre-funded warrants as part of our January 2024 financing, which may cause additional dilution to our shareholders.
  • We have a substantial number of authorized common shares available for future issuance that could cause dilution to our stockholders’ interest and adversely impact the rights of the holders of our shares.
  • The issuance of shares upon exercise of outstanding warrants and options may cause immediate and substantial dilution to our existing stockholders.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • We are a smaller reporting company within the meaning of the Securities Act, and if we continue to decide to take advantage of certain exemptions from various reporting requirements applicable to smaller reporting companies, our common stock could be less attractive to investors.
  • General Risk Factors
  • We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Unfavorable global economic conditions could adversely affect our business, financial condition and stock price.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.

Legal proceedings

For a description of material legal proceedings, see Note 12 to the accompanying consolidated financial statements.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
    SEC EDGAROther events
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68